Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
AstraZeneca will buy about $2 billion of newly issued Summit Therapeutics preferred stock convertible into common shares. The companies also plan a clinical collaboration to evaluate cancer medicines including Sone-Ve and ivonescimab.
The companies also agreed to a clinical trial collaboration to evaluate ivonescimab with sonesitatug vedotin in gastrointestinal cancers. Summit said AstraZeneca’s investment will be in convertible preferred shares.
On Monday, AstraZeneca (NASDAQ: AZN ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit View the webcast at Summary AstraZeneca reported a 6% growth in total revenue for the fi
AZN said it entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment drug Zegfrovy, in a deal valued at up to $1.5B; said it would make an upfront payment of $600B, as well as additional payments of up to $900M of milestones